We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01844505
First Posted: May 1, 2013
Last Update Posted: November 7, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Bristol-Myers Squibb
  Purpose
The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.

Condition Intervention Phase
Unresectable or Metastatic Melanoma Biological: Nivolumab Biological: Ipilimumab Biological: Placebo for Nivolumab Biological: Placebo for Ipilimumab Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: From randomization until disease progression or death, whichever occurred first (assessed up to February 2015, approximately 20 months) ]
    PFS was defined as the time between the date of randomization and the first date of documented progression, as determined by the Investigator, or death due to any cause, whichever occurred first. Progression is defined, using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, and an absolute increase of at least 5 mm. Participants who died without a reported progression were considered to have progressed on the date of their death. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment. Participants who did not have any on study tumor assessments and did not die were censored on their date of randomization. Participants who started anti-cancer therapy without prior reported progression were censored on the date of their last evaluable tumor assessment prior to the initiation of subsequent anti-cancer therapy.

  • Overall Survival (OS) [ Time Frame: From randomization to date of death (Assessed up to September 2016, approximately 39 months) ]
    OS was defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive.

  • Rate of Overall Survival [ Time Frame: 6, 12, and 24 months ]
    OS was defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive. The overall survival rate at time T (6, 12, or 24 months) was defined as the probability that a participant was alive at time T following randomization.

  • Rate of Progression-Free Survival [ Time Frame: 6, 12, and 24 months ]
    PFS was defined as the time between the date of randomization and the first date of documented progression, as determined by the Investigator, or death due to any cause, whichever occurred first. Participants who died without a reported progression were considered to have progressed on the date of their death. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment. Participants who did not have any on study tumor assessments and did not die were censored on their date of randomization. Participants treated beyond progression were considered to have progressive disease at the time of the initial progression event regardless of subsequent tumor response. Participants who started anti-cancer therapy without a prior reported progression were censored on the date of their last evaluable tumor assessment prior to the initiation of subsequent anti-cancer therapy.


Secondary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: From randomization until disease progression or death, whichever occurred first (assessed up to February 2015, approximately 20 months) ]
    PFS data is presented as it was in Primary Outcome Measure #1. The statistical analysis following this outcome measure (#5) reports on a secondary objective comparing PFS between the Nivolumab and Nivolumab + Ipilimumab arms.

  • Overall Survival (OS) [ Time Frame: From randomization to date of death (Assessed up to September 2016, approximately 39 months) ]
    OS data is presented as it was in Primary Outcome Measure #2. The statistical analysis following this outcome measure (#6) reports on a secondary objective comparing OS between the Nivolumab and Nivolumab + Ipilimumab arms.

  • Objective Response Rate (ORR) Per Investigator Assessment [ Time Frame: From randomization until date of disease progression or the date of subsequent anti-cancer therapy, whichever occurs first (Assessed up to February 2015, approximately 20 months) ]
    The ORR was defined as the number of participants with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized participants for each arm. The BOR was defined as the best response designation, as determined by the Investigator, recorded between the date of randomization and the date of progression, as assessed by the Investigator per RECIST 1.1 or the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), whichever occurred first. For participants without evidence of RECIST 1.1 progression or subsequent anticancer therapy, all available response designations contributed to the BOR assessment. CR= Disappearance of all evidence of disease, confirmed by PET scan; PR= Regression of measureable disease and no new sites; Stable Disease (SD)= Failure to attain CR/PR or PD; Progressive Disease (PD)= Any new lesion or increase by >=50% of previously involved sites from nadir.

  • Progression-Free Survival Based on PD-L1 Expression Level [ Time Frame: From randomization until disease progression or death from any cause, whichever occurs first (Assessed up to September 2016, approximately 39 months) ]
    PD-L1 expression was defined as the percent of tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an IHC assay. Tumor biopsy specimens without measurable PD-L1 expression were classified as indeterminate if the staining was hampered for reasons attributed to the biology of the specimen and not because of improper specimen preparation or handling. Missing specimens, specimens that were not optimally collected (ie not evaluable), and all other specimens were classified as unknown. Participants must have been classified as PD-L1 >=5% or PD-L1 <5% per a verified IHC assay, or as indeterminate (ie not unknown), in order to be randomized.

  • Overall Survival Based on PD-L1 Expression Level [ Time Frame: From randomization until date of death (Assessed up to September 2016, approximately 39 months) ]
    OS was defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive.

  • Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status [ Time Frame: Baseline and weeks 5, 7, 11, 13, 17, 19, 23, 25, then every 6 weeks until treatment discontinuation ]
    Health Related Quality of Life was assessed using the EORTC QLQ-C30 questionnaire Version 3. With the exception of 2 items included in the global health/quality of life scale, for which responses range from 1 (Very poor) to 7 (Excellent), item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores for all functional scales and Global Health Status indicate better HRQoL; an increase from baseline indicates improvement in HRQoL compared to baseline. The mean score for all participants in an arm at a given week was subtracted from the mean score of the participants in that arm at baseline. Mean changes from baseline score is presented for all participants in an arm that remained on treatment and completed the EORTC-QLQ-C30 questionnaire at that time point.

  • Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Social Functioning [ Time Frame: Baseline and weeks 5, 7, 11, 13, 17, 19, 23, 25, then every 6 weeks until treatment discontinuation ]
    Health Related Quality of Life was assessed using the EORTC QLQ-C30 questionnaire Version 3. With the exception of 2 items included in the global health/quality of life scale, for which responses range from 1 (Very poor) to 7 (Excellent), item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores for all functional scales and Global Health Status indicate better HRQoL; an increase from baseline indicates improvement in HRQoL compared to baseline.

  • Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Cognitive Functioning [ Time Frame: Baseline and weeks 5, 7, 11, 13, 17, 19, 23, 25, then every 6 weeks until treatment discontinuation ]
    Health Related Quality of Life was assessed using the EORTC QLQ-C30 questionnaire Version 3. With the exception of 2 items included in the global health/quality of life scale, for which responses range from 1 (Very poor) to 7 (Excellent), item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores for all functional scales and Global Health Status indicate better HRQoL; an increase from baseline indicates improvement in HRQoL compared to baseline.

  • Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Emotional Functioning [ Time Frame: Baseline and weeks 5, 7, 11, 13, 17, 19, 23, 25, then every 6 weeks until treatment discontinuation ]
    Health Related Quality of Life was assessed using the EORTC QLQ-C30 questionnaire Version 3. With the exception of 2 items included in the global health/quality of life scale, for which responses range from 1 (Very poor) to 7 (Excellent), item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores for all functional scales and Global Health Status indicate better HRQoL; an increase from baseline indicates improvement in HRQoL compared to baseline.

  • Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Role Functioning [ Time Frame: Baseline and weeks 5, 7, 11, 13, 17, 19, 23, 25, then every 6 weeks until treatment discontinuation ]
    Health Related Quality of Life was assessed using the EORTC QLQ-C30 questionnaire Version 3. With the exception of 2 items included in the global health/quality of life scale, for which responses range from 1 (Very poor) to 7 (Excellent), item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores for all functional scales and Global Health Status indicate better HRQoL; an increase from baseline indicates improvement in HRQoL compared to baseline.

  • Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Functioning [ Time Frame: Baseline and weeks 5, 7, 11, 13, 17, 19, 23, 25, then every 6 weeks until treatment discontinuation ]
    Health Related Quality of Life was assessed using the EORTC QLQ-C30 questionnaire Version 3. With the exception of 2 items included in the global health/quality of life scale, for which responses range from 1 (Very poor) to 7 (Excellent), item responses range from 1 (Not at all) to 4 (Very much). Raw scores for the EORTC QLQ-C30 are transformed to a 0-100 metric such that higher scores for all functional scales and Global Health Status indicate better HRQoL; an increase from baseline indicates improvement in HRQoL compared to baseline.


Enrollment: 1296
Actual Study Start Date: May 23, 2013
Estimated Study Completion Date: March 31, 2019
Primary Completion Date: August 1, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab
Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Ipilimumab 0 mg/kg solution intravenously on weeks 1, 4 and Placebo matching with Nivolumab on weeks 4 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Biological: Nivolumab
Other Names:
  • BMS-936558
  • MDX-1106
Biological: Placebo for Nivolumab Biological: Placebo for Ipilimumab
Experimental: Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab
Nivolumab 1 mg/kg solution intravenously combined with Ipilimumab 3 mg/kg solution intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Nivolumab on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Biological: Nivolumab
Other Names:
  • BMS-936558
  • MDX-1106
Biological: Ipilimumab
Other Names:
  • Yervoy
  • BMS-734016
  • MDX-010
Biological: Placebo for Nivolumab
Experimental: Arm C: Ipilimumab+Placebo for Nivolumab
Ipilimumab 3 mg/kg solution intravenously every 3 weeks for a total of 4 doses plus Placebo matching with Nivolumab 0 mg/kg solution intravenously on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Biological: Ipilimumab
Other Names:
  • Yervoy
  • BMS-734016
  • MDX-010
Biological: Placebo for Nivolumab

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Histologically confirmed stage III (unresectable) or stage IV melanoma
  • Treatment naïve patients
  • Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria
  • Tumor tissue from an unresectable or metastatic site of disease for biomarker analyses
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

Exclusion Criteria:

  • Active brain metastases or leptomeningeal metastases
  • Ocular melanoma
  • Subjects with active, known or suspected autoimmune disease
  • Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment
  • Prior treatment with an anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) antibody
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01844505


  Hide Study Locations
Locations
United States, Arizona
Banner-MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
University Of Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, California
UC San Diego Moores Cancer Ctr
La Jolla, California, United States, 92093-0698
The Angeles Clinic And Research Institute.
Los Angeles, California, United States, 90025
University Of California - Los Angeles
Los Angeles, California, United States, 90095
Comprehensive Cancer Center At Desert Regional Medical Ctr
Palm Springs, California, United States, 92262
Desert Hematology Oncology Medical Group
Rancho Mirage, California, United States, 92270
California Pacific Medical Center Research Institute
San Francisco, California, United States, 94115
Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115
United States, Colorado
University Of Colorado Cancer Center
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06520
United States, District of Columbia
Georgetown University Medical Center
Washington, D.C., District of Columbia, United States, 20007
Medstar Washington Hospital Center
Washington, D.C., District of Columbia, United States, 20010
United States, Florida
Baptist MD Anderson Cancer Center
Jacksonville, Florida, United States, 32207
Orlando Health, Inc
Orlando, Florida, United States, 32806
United States, Georgia
Winship Cancer Institute
Atlanta, Georgia, United States, 30322
United States, Maine
Maine Center For Cancer Medicine
Scarborough, Maine, United States, 04074
United States, Maryland
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Lutherville, Maryland, United States, 21093
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Beth Israel Deaconness Medical Center
Boston, Massachusetts, United States, 02215
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Michigan
University Of Michigan Health System
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
Allina Health
Minneapolis, Minnesota, United States, 55407
United States, Mississippi
University Of Mississippi Medical Center
Jackson, Mississippi, United States, 39216
United States, Missouri
Washington University School Of Medicine
Saint Louis, Missouri, United States, 63110
United States, Nevada
Comprehensive Cancer Centers Of Nevada
Las Vegas, Nevada, United States, 89148
United States, New Jersey
Atlantic Melanoma Center
Morristown, New Jersey, United States, 07962
United States, New Mexico
University Of New Mexico Cancer Center
Albuquerque, New Mexico, United States, 87106
United States, New York
New York Oncology Hematology, Pc
Clifton Park, New York, United States, 12065
NYU Clinical Cancer Center
New York, New York, United States, 10016
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, North Carolina
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
Duke Cancer Institute
Durham, North Carolina, United States, 27710
United States, Ohio
University Hospitals
Cleveland, Ohio, United States, 44106-5048
United States, Oregon
Providence Cancer Center Oncology and Hematology Care- Eastside
Portland, Oregon, United States, 97213
United States, Pennsylvania
Lehigh Valley Health Network
Allentown, Pennsylvania, United States, 18103
St. Luke's Cancer Center - Anderson Campus
Easton, Pennsylvania, United States, 18045
Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
United States, South Carolina
Greenville Health System
Greenville, South Carolina, United States, 29605
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232
United States, Texas
Texas Oncology
Dallas, Texas, United States, 75246
The University Of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
United States, Washington
University of Washington
Seattle, Washington, United States, 98109
Australia, New South Wales
Local Institution
Camperdown, New South Wales, Australia, 2050
Local Institution
Coffs Harbour, New South Wales, Australia, 2450
Local Institution
Gateshead, New South Wales, Australia, 2290
Local Institution
North Sydney, New South Wales, Australia, 2146
Local Institution
Westmead, New South Wales, Australia, 2145
Australia, Queensland
Local Institution
Greenslopes, Queensland, Australia, 4102
Local Institution
Southport, Queensland, Australia, 4215
Local Institution
Woolloongabba, Queensland, Australia, 4102
Australia, South Australia
Local Institution
Adelaide, South Australia, Australia, 5000
Local Institution
Kurralta Park, South Australia, Australia, 5037
Australia, Victoria
Local Institution
Box Hill, Victoria, Australia, 3128
Local Institution
Heidelberg, Victoria, Australia, 3084
Australia, Western Australia
Local Institution
Nedlands, Western Australia, Australia, 6009
Australia
Local Institution
Melbourne, Australia, 3000
Austria
Local Institution
Salzburg, Austria, 5020
Local Institution
Wien, Austria, 1090
Belgium
Local Institution
Brussels, Belgium, 1090
Local Institution
Bruxelles, Belgium, 1200
Local Institution
Edegem, Belgium, 2650
Local Institution
Gent, Belgium, 9000
Local Institution
Leuven, Belgium, 3000
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
BC Cancer Agency - Vancouver Centre
Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Ontario
London Regional Cancer Program
London, Ontario, Canada, N6A 4L6
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada, K1H 8L6
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Chum-Hopital Notre-Dame
Montreal, Quebec, Canada, H2L 4M1
Canada
CHU de Quebec
Quebec, Canada, G1R 2J6
Czechia
Local Institution
Brno, Czechia, 656 53
Local Institution
Hradec Kralove, Czechia, 500 05
Local Institution
Praha 2, Czechia, 128 08
Local Institution
Praha 8, Czechia, 180 81
Denmark
Aarhus University Hospital
Aarhus C, Denmark, 8000
Herlev University Hospital
Herlev, Denmark, 2730
Odense University Hospital
Odense, Denmark, 5000
Finland
Local Institution
Helsinki, Finland, 00029
Local Institution
Tampere, Finland, 33521
France
Local Institution
Boulogne Billancourt, France, 92104
Local Institution
Marseille Cedex 5, France, 13385
Local Institution
Nantes Cedex, France, 44093
Local Institution
Paris Cedex 10, France, 75475
Local Institution
Pierre Benite, France, 69310
Local Institution
Rennes, France, 35042
Local Institution
Villejuif, France, 94805
Germany
Local Institution
Buxtehude, Germany, 21614
Local Institution
Erfurt, Germany, 99089
Local Institution
Erlangen, Germany, 91054
Local Institution
Essen, Germany, 45147
Local Institution
Hannover, Germany, 30625
Local Institution
Heidelberg, Germany, 69120
Local Institution
Kiel, Germany, 24105
Local Institution
Leipzig, Germany, 04103
Local Institution
Munich, Germany, 80337
Local Institution
Tubingen, Germany, 72076
Ireland
Local Institution
Cork, Ireland
Local Institution
Dublin, Ireland, 01
Local Institution
Dublin, Ireland, 7
Local Institution
Dublin, Ireland
Local Institution
Galway, Ireland
Israel
Local Institution
Jerusalem, Israel, 91120
Local Institution
Tel Hashomer, Israel, 52621
Italy
Local Institution
Bergamo, Italy, 24127
Local Institution
Genova, Italy, 16132
Local Institution
Meldola (FC), Italy, 47014
Local Institution
Milano, Italy, 20133
Local Institution
Milano, Italy, 20141
Local Institution
Napoli, Italy, 80131
Local Institution
Padova, Italy, 35128
Local Institution
Roma, Italy, 00144
Local Institution
Siena, Italy, 53100
Netherlands
Local Institution
Amsterdam, Netherlands, 1066 CX
Local Institution
Leiden, Netherlands, 2333 ZA
Local Institution
Nijmegen, Netherlands, 6525 GA
New Zealand
Local Institution
Auckland, New Zealand, 1142
Norway
Local Institution
Oslo, Norway, 0424
Poland
Local Institution
Bydgoszcz, Poland, 85-792
Local Institution
Gdansk, Poland, 80-952
Local Institution
Krakow, Poland, 31-115
Local Institution
Lodz, Poland, 93-513
Local Institution
Warsaw, Poland, 02-781
Spain
Local Institution
Badalona-Barcelona, Spain, 08916
Local Institution
Barcelona, Spain, 08035
Local Institution
Barcelona, Spain, 08036
Local Institution
Madrid, Spain, 28007
Local Institution
Madrid, Spain, 28046
Local Institution
Malaga, Spain, 29010
Local Institution
Pamplona-Navarra, Spain, 31192
Sweden
Local Institution
Gothenberg, Sweden, 413 45
Local Institution
Stockholm, Sweden, 171 76
Switzerland
Local Institution
Geneva, Switzerland, 1211
Local Institution
Lausanne, Switzerland, 1011
Local Institution
St. Gallen, Switzerland, 9007
Local Institution
Zürich, Switzerland, 8091
United Kingdom
Local Institution
Cambridge, Cambridgeshire, United Kingdom, CB2 2QQ
Local Institution
Swansea, Carmarthenshire, United Kingdom, SA2 8QA
Local Institution
Glasgow, Dumfries & Galloway, United Kingdom, G12 0YN
Local Institution
London, Greater London, United Kingdom, SW3 6JJ
Local Institution
Manchester, Greater Manchester, United Kingdom, M20 4XB
Local Institution
Northwood, Middlesex, United Kingdom, HA6 2JR
Local Institution
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01844505     History of Changes
Other Study ID Numbers: CA209-067
2012-005371-13 ( EudraCT Number )
First Submitted: April 29, 2013
First Posted: May 1, 2013
Results First Submitted: July 14, 2017
Results First Posted: September 26, 2017
Last Update Posted: November 7, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Nivolumab
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs